Glucosio Con Potassio Cloruro Ii Bioindustria L.I.M.

Glucosio Con Potassio Cloruro Ii, marketed by Bioindustria L.I.M., is an injectable solution that combines potassium chloride and glucose monohydrate in a single formulation; the exact strength is not disclosed on the label. Designed for intravenous administration, this prescription‑only product is intended for use in clinical settings within the European Union. It functions as an electrolyte supplement and glucose source to support fluid and electrolyte therapy.

Glucosio Con Potassio Cloruro Ii is indicated for several clinical situations where potassium and energy replenishment are required.

- Treatment of hypokalemia or potassium depletion in hospitalized patients. - Fluid replacement therapy during postoperative recovery or acute illness. - Prevention of electrolyte imbalance in patients undergoing major surgery. - Support of intracellular fluid shifts when combined with other IV fluids. - Adjunctive therapy for patients receiving insulin to mitigate hypoglycemia‑induced potassium shifts. - Correction of potassium loss associated with diuretic therapy in critical‑care settings.

Side‑effect profiles for Glucosio Con Potassio Cloruro Ii reflect the pharmacologic actions of potassium chloride and glucose when administered intravenously. These events are generally dose‑dependent and monitored during therapy, occasionally requiring adjustment.

Common: - Mild transient hyperglycemia due to glucose infusion. - Local irritation or pain at the injection site. - Slight increase in serum potassium that may cause mild muscle weakness. - Nausea or vomiting related to rapid glucose administration.

Serious: - Severe hyperkalemia leading to cardiac arrhythmias. - Hyperosmolar hyperglycemic state in patients with impaired glucose tolerance. - Allergic or anaphylactic reaction to the formulation components. - Metabolic acidosis secondary to rapid potassium infusion in patients with renal impairment.

When prescribing Glucosio Con Potassio Cloruro Ii, clinicians should evaluate patient‑specific factors to minimize risks associated with potassium and glucose administration.

- Verify baseline serum potassium and glucose levels before infusion. - Adjust dose in patients with renal insufficiency or on dialysis. - Use caution in individuals with cardiac disease or arrhythmias. - Avoid rapid infusion rates to reduce the risk of hyperkalemia. - Monitor cardiac rhythm and blood pressure during and after administration. - Consider alternative fluid therapy for patients with known hypersensitivity to formulation excipients.

Glucosio Con Potassio Cloruro Ii may interact with other medications that affect potassium balance, glucose metabolism, or cardiac conduction.

Avoid: - Concurrent use with potassium‑sparing diuretics or ACE inhibitors without electrolyte monitoring. - Co‑administration with rapid‑acting insulin boluses in uncontrolled diabetes. - Avoid simultaneous infusion with calcium gluconate solutions, as they may precipitate potassium chloride.

Use with caution: - Combine with other IV fluids containing potassium; adjust total potassium load. - Use alongside beta‑adrenergic agonists, which can shift potassium intracellularly. - Administer with nephrotoxic drugs; monitor renal function closely. - Give together with medications that prolong QT interval; observe ECG changes.